Skip to main content

Research Repository

Advanced Search

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

Papapetropoulos, Andreas; Topouzis, Stavros; Alexander, Steve P. H.; Cortese‐Krott, Miriam; Kendall, Dave A.; Martemyanov, Kirill A.; Mauro, Claudio; Nagercoil, Nithyanandan; Panettieri, Reynold A.; Patel, Hemal H.; Schulz, Rainer; Stefanska, Barbara; Stephens, Gary J.; Teixeira, Mauro M.; Vergnolle, Nathalie; Wang, Xin; Ferdinandy, Péter

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review Thumbnail


Authors

Andreas Papapetropoulos

Stavros Topouzis

Miriam Cortese‐Krott

Dave A. Kendall

Kirill A. Martemyanov

Claudio Mauro

Nithyanandan Nagercoil

Reynold A. Panettieri

Hemal H. Patel

Rainer Schulz

Barbara Stefanska

Gary J. Stephens

Mauro M. Teixeira

Nathalie Vergnolle

Péter Ferdinandy



Abstract

In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as “first-in-class” (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first-ever approval of a CRISPR-Cas9-based gene-editing cell therapy.

Citation

Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese‐Krott, M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., Wang, X., & Ferdinandy, P. (2024). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology, 181(11), 1553-1575. https://doi.org/10.1111/bph.16337

Journal Article Type Review
Acceptance Date Jan 29, 2024
Online Publication Date Mar 22, 2024
Publication Date Mar 22, 2024
Deposit Date Apr 15, 2024
Publicly Available Date Apr 16, 2024
Journal British Journal of Pharmacology
Print ISSN 0007-1188
Electronic ISSN 1476-5381
Publisher Wiley
Peer Reviewed Not Peer Reviewed
Volume 181
Issue 11
Pages 1553-1575
DOI https://doi.org/10.1111/bph.16337
Keywords FDA, MHRA, EMA, drug development, new drug approvals, regulatory
Public URL https://nottingham-repository.worktribe.com/output/33012819
Publisher URL https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16337
Additional Information Received: 2024-01-27; Accepted: 2024-01-29; Published: 2024-03-22

Files

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review (3.8 Mb)
PDF

Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/

Copyright Statement
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.





You might also like



Downloadable Citations